IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Lowered by Impax Asset Management Group plc

Impax Asset Management Group plc reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 90.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,826 shares of the medical research company's stock after selling 181,377 shares during the period. Impax Asset Management Group plc's holdings in IQVIA were worth $3,495,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. American National Bank & Trust purchased a new stake in shares of IQVIA in the 1st quarter valued at $26,000. Golden State Wealth Management LLC increased its stake in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares during the period. ST Germain D J Co. Inc. increased its stake in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the period. GKV Capital Management Co. Inc. purchased a new stake in IQVIA during the 4th quarter worth approximately $39,000. Finally, Lee Danner & Bass Inc. purchased a new stake in IQVIA during the 4th quarter worth approximately $44,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on IQV shares. HSBC lowered IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. UBS Group cut their target price on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Barclays dropped their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Finally, Citigroup reiterated a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Stock Down 0.9%

Shares of NYSE:IQV traded down $1.52 during midday trading on Monday, reaching $162.73. The company had a trading volume of 311,090 shares, compared to its average volume of 1,648,581. The stock's fifty day moving average price is $150.86 and its 200-day moving average price is $173.03. The stock has a market capitalization of $28.15 billion, a P/E ratio of 22.25, a PEG ratio of 1.82 and a beta of 1.30. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. During the same period in the previous year, the company earned $2.54 earnings per share. IQVIA's quarterly revenue was up 2.5% on a year-over-year basis. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.